

# Novavax to Participate in Upcoming September Conferences

September 8, 2023

GAITHERSBURG, Md., Sept. 8, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences.

## **H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference:**

### *Fireside Chat*

Date: Monday, September 11, 2023  
Time: 4:30 – 5:00 p.m. Eastern Daylight Time (EDT)  
Location: Lotte New York Palace Hotel  
Moderator: Vernon Bernardino, Managing Director, Senior Healthcare Analyst  
Novavax participants: Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer and Robert Walker, Senior Vice President, Chief Medical Officer

### *Conference*

Event: Investor Meetings  
Date: Monday, September 11, 2023

## **Baird 2023 Global Healthcare Conference:**

### *Fireside Chat*

Date: Tuesday, September 12, 2023  
Time: 10:15 – 10:45 a.m. EDT  
Location: Intercontinental New York Barclay Hotel  
Moderator: Joel L. Beatty, MD, CFA, Senior Research Analyst – Biotechnology  
Novavax participants: Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer and Robert Walker, Senior Vice President, Chief Medical Officer

### *Conference*

Event: Investor Meetings  
Date: Tuesday, September 12, 2023

A replay of the recorded fireside sessions will be available through the Events and Presentations page of the Company's website at [ir.novavax.com](https://ir.novavax.com) for 90 days from the date of the conference.

## **About Novavax**

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza and COVID and influenza combined. Please visit [novavax.com](https://novavax.com) and [LinkedIn](#) for more information.

## **Contacts:**

### Investors

Erika Schultz  
240-268-2022  
[ir@novavax.com](mailto:ir@novavax.com)

### Media

Ali Chartan  
240-720-7804  
[media@novavax.com](mailto:media@novavax.com)



SOURCE Novavax, Inc.